Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma

被引:0
|
作者
Matthew J. Ahearne
Kaljit Bhuller
Roger Hew
Hazem Ibrahim
Kikkeri Naresh
Simon D. Wagner
机构
[1] University of Leicester,Department of Cancer Studies and Molecular Medicine, Ernest and Helen Scott Haematology Research Institute and MRC Toxicology Unit
[2] Leicester Royal Infirmary,Department of Haematology
[3] Leicester Royal Infirmary,Department of Histopathology
[4] Imperial College Healthcare NHS Trust,Department of Histopathology
[5] University of Leicester,MRC Toxicology Unit
来源
Virchows Archiv | 2014年 / 465卷
关键词
Tfh; Treg; Diffuse large B-cell lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
The role of the microenvironment in high-grade lymphoma is not well defined. In this report, we employ immunohistochemistry to characterise programmed death-1 (PD-1/CD279) and FoxP3 expression in 70 cases of diffuse large B-cell lymphoma (DLBCL). PD-1 is a surface marker characteristic of follicular helper T-cells whilst FoxP3 is characteristic of Tregs. We demonstrate variable infiltration with CD4+ T-cells (<10 to >50 % of all lymph node cells) and PD-1hi cells (0.1 to 1.5 % of all cells). CD4+ T-cells can be distributed in clusters or more diffusely and PD-1hi cells, but not FoxP3+ cells, are found in rosettes around lymphoma cells. Cases with high CD4+ T-cell numbers tended to have higher numbers of both PD-1hi and FoxP3+ cells. Cases with total CD4+ T-cell, PD-1hi and FoxP3+ numbers above the median associate with better clinical outcome. Overall, we demonstrate that infiltration by CD4+ T-cells, including both FoxP3+ and PD-1hi subsets, correlates with prognosis in DLBCL. In distinction to previous reported series, patients (91 %) were treated with rituximab-containing regimens, suggesting that the effects of CD4+ T-cell infiltration are maintained in the rituximab era. This work suggests that determinants of total CD4+ T-cell infiltration, either molecular characteristics of the lymphoma or the patients’ immune system, and not individual T-cell subsets, correlate with clinical outcome.
引用
收藏
页码:351 / 358
页数:7
相关论文
共 50 条
  • [11] Prognostic value of PD-1 and TIM-3 on CD3+T cells from diffuse large B-cell lymphoma
    Zhang, Li
    Du, Hui
    Xiao, Tai-wu
    Liu, Ji-zhu
    Liu, Guo-zhen
    Wang, Jing-xia
    Li, Guang-yao
    Wang, Le-xin
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 75 : 83 - 87
  • [12] PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
    Frigault, Matthew J.
    Armand, Philippe
    Redd, Robert A.
    Jeter, Erin
    Merryman, Reid W.
    Coleman, Kimberly C.
    Herrera, Alex F.
    Dahi, Parastoo
    Nieto, Yago
    LaCasce, Ann S.
    Fisher, David C.
    Ng, Samuel Y.
    Odejide, Oreife O.
    Freedman, Arnold S.
    Kim, Austin, I
    Crombie, Jennifer L.
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Wong, Jeffrey L.
    Bsat, Jad
    Patel, Sanjay S.
    Ritz, Jerome
    Rodig, Scott J.
    Shipp, Margaret A.
    Chen, Yi-Bin
    Joyce, Robin M.
    BLOOD ADVANCES, 2020, 4 (01) : 122 - 126
  • [13] PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation
    Chen, Yi-Bin
    Armand, Philippe
    Redd, Robert A.
    Bsat, Jad
    Merryman, Reid W.
    Coleman, Kimberly
    Herrera, Alex F.
    Dahi, Parastoo B.
    Nieto, Yago
    LaCasce, Ann S.
    Fisher, David C.
    Ng, Samuel Y.
    Odejide, Oreofe O.
    Freedman, Arnold S.
    Kim, Austin I.
    Crombie, Jennifer L.
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Wong, Jeffrey L.
    Patel, Sanjay S.
    Ritz, Jerome
    Rodig, Scott J.
    Shipp, Margaret A.
    Joyce, Robin M.
    BLOOD, 2018, 132
  • [14] PD1 expression in diffuse large B-cell lymphoma: pilot study
    Oparnica, V.
    Ostojic, M.
    Prvanovic, M.
    Boricic, N.
    Terzic, T.
    VIRCHOWS ARCHIV, 2019, 475 : S341 - S342
  • [15] EBV plus Diffuse Large B-Cell Lymphoma, NOS Shows Over-Expression of PD-L1/PD-1
    Jagannathan, Geetha
    Gong, Jerald
    Uppal, Guldeep
    LABORATORY INVESTIGATION, 2018, 98 : 525 - 525
  • [16] The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
    Fang, Xia
    Xiu, Bing
    Yang, Zhizhang
    Qiu, Weizhe
    Zhang, Long
    Zhang, Suxia
    Wu, Yunjin
    Zhu, Xuyou
    Chen, Xue
    Xie, Suhong
    Yi, Xianghua
    Liang, Aibin
    Zeng, Yu
    MEDICINE, 2017, 96 (15)
  • [17] EBV plus Diffuse Large B-Cell Lymphoma, NOS Shows Over-Expression of PD-L1/PD-1
    Jagannathan, Geetha
    Gong, Jerald
    Uppal, Guldeep
    MODERN PATHOLOGY, 2018, 31 : 525 - 525
  • [18] CD30 Expression in Diffuse Large B-Cell Lymphoma
    Slack, Graham W.
    Steidl, Christian
    Sehn, Laurie H.
    Gascoyne, Randy D.
    BLOOD, 2012, 120 (21)
  • [19] Expression of CD30 in diffuse large B-cell lymphoma
    Liasnichaya, O. V.
    Malashenka, S. V.
    Katin, M. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1221 - S1221
  • [20] Expression of programmed death-1 (CD279) in primary cutaneous B-cell lymphomas with correlation to lymphoma entities and biological behaviour
    Mitteldorf, C.
    Bieri, M.
    Wey, N.
    Kerl, K.
    Kamarachev, J.
    Pfaltz, M.
    Kutzner, H.
    Roncador, G.
    Tomasini, D.
    Kempf, W.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (06) : 1212 - 1218